SIMD 2019 Poster: Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers
The results of a randomized, double-blind, placebo- and active treatment-controlled study arepresented in thisposter at the 2019 Society for Inherited Metabolic Disorders (SIMD) Annual Meeting in Seattle
The study design, pharmacokinetic data and safety and tolerability of CNSA-001, a preparation of sepiapterin which is being investigated for treatment of BH4-responsive phenylketonuria (PKU) and primary BH4 deficiencies, are reported in this poster
83 healthy volunteers were randomized into cohorts to receive different doses of CNSA-001, active control (sapropterin dihydrochloride) or placebo: a single administration in Part A, with multiple doses given in Part B. Safety and tolerability results are also presented
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-PKU-2100024 | October 2021
Sign in or register to access exclusive content on this site
Some cookies are essential, others help us improve your experience by providing insights into how the website is used. Select one or more of the cookie types listed below, and then save your preferences. Refer to our Cookies Statement for more information.
Performance cookies, which help us measure the website’s performance and improve your experience. In using performance cookies we do not store any personal data, and only use the information collected through these cookies in aggregated and anonymised form.